Neurotoxicity of Alzheimer's disease Aβ peptides is induced by small changes in the Aβ42 to Aβ40 ratio

[1]  Jin-Moo Lee,et al.  Amyloid seeds formed by cellular uptake, concentration, and aggregation of the amyloid-beta peptide , 2009, Proceedings of the National Academy of Sciences.

[2]  D. Teplow,et al.  Structure-neurotoxicity relationships of amyloid β-protein oligomers , 2009, Neuroscience Research.

[3]  G. Zamponi.  Faculty Opinions recommendation of Cellular prion protein mediates impairment of synaptic plasticity by amyloid-beta oligomers. , 2009 .

[4]  G. Alexander,et al.  Fibrillar amyloid-β burden in cognitively normal people at 3 levels of genetic risk for Alzheimer's disease , 2009, Proceedings of the National Academy of Sciences.

[5]  John W. Gilbert,et al.  Cellular Prion Protein Mediates Impairment of Synaptic Plasticity by Amyloid-β Oligomers , 2009, Nature.

[6]  Jeffrey A. James,et al.  Frequent amyloid deposition without significant cognitive impairment among the elderly. , 2008, Archives of neurology.

[7]  Hans-Ulrich Demuth,et al.  Glutaminyl cyclase inhibition attenuates pyroglutamate Aβ and Alzheimer's disease–like pathology , 2008, Nature Medicine.

[8]  W. K. Cullen,et al.  Amyloid β Protein Dimer-Containing Human CSF Disrupts Synaptic Plasticity: Prevention by Systemic Passive Immunization , 2008, The Journal of Neuroscience.

[9]  S. Bottomley,et al.  Stabilization of Neurotoxic Soluble β-Sheet-Rich Conformations of the Alzheimer's Disease Amyloid-β Peptide , 2008 .

[10]  Chunyu Wang,et al.  Aβ40 Protects Non-toxic Aβ42 Monomer from Aggregation , 2007 .

[11]  S. Halpain,et al.  Rapid, concurrent alterations in pre- and postsynaptic structure induced by naturally-secreted amyloid-β protein , 2007, Molecular and Cellular Neuroscience.

[12]  B. Strooper.  Loss-of-function presenilin mutations in Alzheimer disease. Talking Point on the role of presenilin mutations in Alzheimer disease. , 2007 .

[13]  W. Klein,et al.  Aβ Oligomer-Induced Aberrations in Synapse Composition, Shape, and Density Provide a Molecular Basis for Loss of Connectivity in Alzheimer's Disease , 2007, The Journal of Neuroscience.

[14]  D. Dickson,et al.  Aβ40 Inhibits Amyloid Deposition In Vivo , 2007, The Journal of Neuroscience.

[15]  R. Hepler,et al.  Solution State Characterization of Amyloid β-Derived Diffusible Ligands , 2006 .

[16]  Runsheng Wang,et al.  Wild-type Presenilin 1 Protects against Alzheimer Disease Mutation-induced Amyloid Pathology* , 2006, Journal of Biological Chemistry.

[17]  Y. Ihara,et al.  Equimolar Production of Amyloid β-Protein and Amyloid Precursor Protein Intracellular Domain from β-Carboxyl-terminal Fragment by γ-Secretase* , 2006, Journal of Biological Chemistry.

[18]  M. Gallagher,et al.  A specific amyloid-β protein assembly in the brain impairs memory , 2006, Nature.

[19]  B. Strooper,et al.  Presenilin clinical mutations can affect γ‐secretase activity by different mechanisms , 2006, Journal of neurochemistry.

[20]  R. Rydel,et al.  Nucleation-Dependent Polymerization Is an Essential Component of Amyloid-Mediated Neuronal Cell Death , 2005, The Journal of Neuroscience.

[21]  F. Kametani,et al.  Longer Forms of Amyloid β Protein: Implications for the Mechanism of Intramembrane Cleavage by γ-Secretase , 2005, The Journal of Neuroscience.

[22]  C. Finch,et al.  Alzheimer's disease-affected brain: Presence of oligomeric Aβ ligands (ADDLs) suggests a molecular basis for reversible memory loss , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Ulrich Egert,et al.  Biological application of microelectrode arrays in drug discovery and basic research , 2003, Analytical and bioanalytical chemistry.

[24]  Y. Ihara,et al.  Potential Link between Amyloid β-Protein 42 and C-terminal Fragment γ 49–99 of β-Amyloid Precursor Protein* , 2003, Journal of Biological Chemistry.

[25]  A. Takashima,et al.  Specific Compositions of Amyloid-β Peptides as the Determinant of Toxic β-Aggregation* , 2003, Journal of Biological Chemistry.

[26]  Carl W. Cotman,et al.  Common Structure of Soluble Amyloid Oligomers Implies Common Mechanism of Pathogenesis , 2003, Science.

[27]  C. Yip,et al.  Co-incorporation of Aβ40 and Aβ42 to form mixed pre-fibrillar aggregates , 2003 .

[28]  P. Lansbury,et al.  Neurodegenerative disease: Amyloid pores from pathogenic mutations , 2002, Nature.

[29]  P. Jones,et al.  Neurodegenerative disease: Amyloid pores from pathogenic mutations , 2002, Nature.

[30]  W. K. Cullen,et al.  Naturally secreted oligomers of amyloid β protein potently inhibit hippocampal long-term potentiation in vivo , 2002, Nature.

[31]  Steve M. Potter,et al.  A new approach to neural cell culture for long-term studies , 2001, Journal of Neuroscience Methods.

[32]  C M Dobson,et al.  Ultrastructural organization of amyloid fibrils by atomic force microscopy. , 2000, Biophysical journal.

[33]  Dominic M. Walsh,et al.  Protofibrillar Intermediates of Amyloid β-Protein Induce Acute Electrophysiological Changes and Progressive Neurotoxicity in Cortical Neurons , 1999, The Journal of Neuroscience.

[34]  J. Morris,et al.  Tangles and plaques in nondemented aging and “preclinical” Alzheimer's disease , 1999, Annals of neurology.

[35]  T. Morgan,et al.  Diffusible, nonfibrillar ligands derived from Abeta1-42 are potent central nervous system neurotoxins. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[36]  J. Hardy,et al.  Increased amyloid-β42(43) in brains of mice expressing mutant presenilin 1 , 1996, Nature.

[37]  T. Iwatsubo,et al.  Amino- and carboxyl-terminal heterogeneity of β-amyloid peptides deposited in human brain , 1996, Neuroscience Letters.

[38]  G. Schellenberg,et al.  Secreted amyloid β–protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease , 1996, Nature Medicine.

[39]  S. M. Sumi,et al.  Amyloid β protein (Aβ) deposition in chromosome 14–linked Alzheimer's disease: Predominance of Aβ42(43) , 1996 .

[40]  D. Butterfield,et al.  Glutamine Synthetase‐Induced Enhancement of β‐Amyloid Peptide Aβ(1–40) Neurotoxicity Accompanied by Abrogation of Fibril Formation and Aβ Fragmentation , 1996 .

[41]  Carl W. Cotman,et al.  Amino-terminal Deletions Enhance Aggregation of β-Amyloid Peptides in Vitro(*) , 1995, The Journal of Biological Chemistry.

[42]  T. Holzman,et al.  Amyloid-beta aggregation: selective inhibition of aggregation in mixtures of amyloid with different chain lengths. , 1994, Biophysical journal.

[43]  S. Younkin,et al.  An increased percentage of long amyloid beta protein secreted by familial amyloid beta protein precursor (beta APP717) mutants. , 1994, Science.

[44]  D. Selkoe,et al.  Cellular processing of β-amyloid precursor protein and the genesis of amyloid β-peptide , 1993, Cell.

[45]  P. Lansbury,et al.  Seeding “one-dimensional crystallization” of amyloid: A pathogenic mechanism in Alzheimer's disease and scrapie? , 1993, Cell.

[46]  D. Salmon,et al.  Physical basis of cognitive alterations in alzheimer's disease: Synapse loss is the major correlate of cognitive impairment , 1991, Annals of neurology.

[47]  J. Pine.  Recording action potentials from cultured neurons with extracellular microcircuit electrodes , 1980, Journal of Neuroscience Methods.

[48]  N. Nevskaya,et al.  Infrared spectra and resonance interaction of amide‐I vibration of the antiparallel‐chain pleated sheet , 1976, Biopolymers.

[49]  B. de Strooper.  Proteases and proteolysis in Alzheimer disease: a multifactorial view on the disease process. , 2010, Physiological reviews.

[50]  J. Hardy,et al.  The Amyloid Hypothesis of Alzheimer ’ s Disease : Progress and Problems on the Road to Therapeutics , 2009 .

[51]  S. Bottomley,et al.  Stabilization of neurotoxic soluble beta-sheet-rich conformations of the Alzheimer's disease amyloid-beta peptide. , 2008, Biophysical journal.

[52]  Chunyu Wang,et al.  Abeta40 protects non-toxic Abeta42 monomer from aggregation. , 2007, Journal of molecular biology.

[53]  R. D'Hooge,et al.  Lipids revert inert Ab amyloid fibrils to neurotoxic protofibrils that affect learning in mice , 2007 .

[54]  D. Dickson,et al.  Abeta40 inhibits amyloid deposition in vivo. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[55]  W. Klein,et al.  Abeta oligomer-induced aberrations in synapse composition, shape, and density provide a molecular basis for loss of connectivity in Alzheimer's disease. , 2007, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[56]  Michela Gallagher,et al.  A specific amyloid-beta protein assembly in the brain impairs memory. , 2006, Nature.

[57]  R. Hepler,et al.  Solution state characterization of amyloid beta-derived diffusible ligands. , 2006, Biochemistry.

[58]  Y. Ihara,et al.  Equimolar production of amyloid beta-protein and amyloid precursor protein intracellular domain from beta-carboxyl-terminal fragment by gamma-secretase. , 2006, The Journal of biological chemistry.

[59]  D. Selkoe,et al.  Natural oligomers of the amyloid-β protein specifically disrupt cognitive function , 2005, Nature Neuroscience.

[60]  F. Kametani,et al.  Longer forms of amyloid beta protein: implications for the mechanism of intramembrane cleavage by gamma-secretase. , 2005, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[61]  A. Takashima,et al.  Specific compositions of amyloid-beta peptides as the determinant of toxic beta-aggregation. , 2003, The Journal of biological chemistry.

[62]  C. Yip,et al.  Co-incorporation of A beta 40 and A beta 42 to form mixed pre-fibrillar aggregates. , 2003, European journal of biochemistry.

[63]  B. de Strooper,et al.  A cell biological perspective on Alzheimer's disease. , 2002, Annual review of cell and developmental biology.

[64]  Weiming Xia,et al.  Mutant presenilins of Alzheimer's disease increase production of 42-residue amyloid β-protein in both transfected cells and transgenic mice , 1997, Nature Medicine.

[65]  P. Lansbury,et al.  Models of amyloid seeding in Alzheimer's disease and scrapie: mechanistic truths and physiological consequences of the time-dependent solubility of amyloid proteins. , 1997, Annual review of biochemistry.

[66]  J. Hardy,et al.  Secreted amyloid beta-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease. , 1996, Nature medicine.

[67]  S. M. Sumi,et al.  Amyloid beta protein (Abeta) deposition in chromosome 14-linked Alzheimer's disease: predominance of Abeta42(43). , 1996, Annals of neurology.

[68]  D. Butterfield,et al.  Glutamine synthetase-induced enhancement of beta-amyloid peptide A beta (1-40) neurotoxicity accompanied by abrogation of fibril formation and A beta fragmentation. , 1996, Journal of neurochemistry.

[69]  C. Cotman,et al.  Amino-terminal deletions enhance aggregation of beta-amyloid peptides in vitro. , 1995, The Journal of biological chemistry.

[70]  E. Goormaghtigh,et al.  Determination of soluble and membrane protein structure by Fourier transform infrared spectroscopy. II. Experimental aspects, side chain structure, and H/D exchange. , 1994, Sub-cellular biochemistry.

[71]  E Goormaghtigh,et al.  Determination of soluble and membrane protein structure by Fourier transform infrared spectroscopy. I. Assignments and model compounds. , 1994, Sub-cellular biochemistry.

[72]  D. Selkoe,et al.  Cellular processing of beta-amyloid precursor protein and the genesis of amyloid beta-peptide. , 1993, Cell.

[73]  N. Nevskaya,et al.  Infrared spectra and resonance interaction of amide-I vibration of the paraellel-chain pleated sheets. , 1976, Biopolymers.